Back to search

Article

IP-10 Predicts Clinical Progression and Response to IL-6 Blockade with Sarilumab in Early COVID-19 Pneumonia. The SARICOR Clinical Trial

2022-10-07

Abstract excerpt

Background and objectives: SARICOR clinical trial (CT) showed that patients with COVID19 pneumonia and increased levels of interleukin (IL)-6 might benefit from early blockade of IL6-pathway. However, the benefit from this intervention might not be uniform in all patients. We sought to determine if other biomarkers of immunoactivation, besides IL-6, could identify which subgroup of patients benefit the most of thi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7d962368-f48e-5f02-a311-64e872d4c895
DOI
10.2139/ssrn.4238635
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
IP-10 Predicts Clinical Progression and Response to IL-6 Blockade with Sarilumab in Early COVID-19 Pneumonia. The SARICOR Clinical TrialDOI 10.2139/ssrn.4238635
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failureSemantic proximity
Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity
Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE TrialSemantic proximity
Prognostic value of Th1/Th2/Th17-related cytokines in severe pneumoniaSemantic proximity
A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity
Dynamic changes in serum IL-6, IL-8, and IL-10 are associated with the outcome of patients with severe COVID-19 in ICUSemantic proximity
Lung Protection vs. Infection Resolution: Interleukin 10 Suspected of Double-Dealing in COVID-19.Semantic proximity
Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumoniaSemantic proximity
Select a neighboring publication to make it the new centre.